Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Abstract: In one aspect, the present application relates to an aminothiol-conjugate of formula (I): wherein R1, R2, R3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).

Abstract: Disclosed herein is a method of using a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. The hyaluronan conjugates are used in treating neurodegenerative diseases.

Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.

Abstract: The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker having a primary amine residue, said linker having the peptide structure (shown in N->C direction) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, or (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, to a Gln residue comprised in the heavy or light chain of an antibody. Aax(NH2) is an amino acid, amino acid derivative or amino acid mimetic comprising a side chain having a primary amine group.

Abstract: The disclosure discloses a glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and a preparation method thereof, and belongs to the field of biomedicine. The disclosure loads a chemotherapeutic drug onto specific metal-organic frameworks, and modifies targeted molecule galactose on the surface of the materials through amide reaction. The biocompatibility and cytotoxicity of the obtained hepatic targeted therapeutic drug have been carefully evaluated at the cellular level. The hepatic targeted therapeutic drug of the disclosure has good stability and acidic pH triggered drug release property, and can exert the synergistic therapeutic effect of photodynamic therapy and chemotherapy. In addition, in vivo behavioral tracing and therapeutic efficacy are evaluated in mouse models with subcutaneous solid tumor and tumor in situ, and the disclosure is expected to play a huge role in clinical applications.

Abstract: Produced the gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 for the treatment of diseases featuring disruption of mucociliary transport, mucolytic function and development of mucostasis. The gene therapy DNA vector contains the coding region of the SKI, TGFB3, TIMP2 or FMOD therapeutic genes. Methods of producing or use a gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying SKI, TGFB3, TIMP2 or FMOD therapeutic genes. The methods of producing strain for production of gene therapy DNA vector for treatment of diseases featuring disruption of mucociliary transport and development of mucostasis. Escherichia coli strain SCS 110-AF/VTvaf17-SKI, SCS 110-AF/VTvaf17-TGFB3, SCS110-AF/VTvaf17-TIMP2 or SCSI 10-AF/VTvaf17-FMOD obtains by the method described above carrying gene therapy DNA vector VTvaf17-SKI, VTvaf17-TGFB3, VTvaf17-TIMP2 or VTvaf17-FMOD.

Abstract: The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

Abstract: The invention relates to a new lutetium-177 therapeutic radiopharmaceutical as an inhibitor of prostate-specific membrane antigen (iPSMA), wherein 1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid (DOTA) bonded to the heterocyclic molecule hydrazinonicotinamide (HYNIC), generates a rigid chemical structure that minimises the number of conformers and intramolecular hydrogen bonds, thereby producing a favourable spatial orientation of the active site (Lys(Nal)-NH—CO—NH-Glu) in the molecule, for biological recognition by the PSMA protein. The new 177Lu-DOTA-HYNIC-iPSMA radiopharmaceutical accumulates, with high affinity in vivo, in tumours that overexpress the PSMA protein, acting as a radiotherapeutic agent. The purpose of the invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) for the treatment of tumours with PSMA overexpression.

Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(?O)NHRa; each of R5-R12 is independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.

Abstract: A cleansing composition comprising a detersive surfactant; an aqueous carrier; from about 0.5% to about 30% by weight of the cleansing composition of discrete particles comprising anhydrous particles and an aqueous phase, and wherein said anhydrous particles comprise: one or more fatty amphiphile selected from the group consisting of fatty alcohol, fatty ester, fatty acid, fatty amide and mixtures thereof; of one or more secondary surfactants selected from the group consisting of anionic, nonionic, zwitterionic, cationic or mixtures thereof. Wherein the discrete particle of the cleansing composition has a size from about 500 microns to about 7000 microns, and wherein the cleansing composition has a % transmittance of about 75% or higher.

Abstract: The present specification describes a method for manufacturing porous inorganic particles and a light-reflecting composition comprising porous inorganic particles. According to an embodiment of the present disclosure it is possible to provide a method for manufacturing porous inorganic particles capable of selective transmission or scattering of light having a specific wavelength range by controlling pore size and shell thickness.

Abstract: An aerosol hairspray product with a spray device and a pressurizable container having a container wall which encloses a reservoir for storing a compressed gas propellant and a hairspray composition. The hairspray composition can be ethanol-based or ethanol-free. The spray properties of the product, including the spray rate and median droplet size, can be maintained throughout the lifetime of the container.

Abstract: The instant disclosure relates to essentially anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more bis-urea derivatives; and one or more solvents. Additional components such as silicones, auxiliary agents, etc., can also be included. The instant disclosure also relates to kits that include the essentially anhydrous hair-treatment compositions and to methods for treating hair with the essentially anhydrous hair-treatment compositions.

Abstract: An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment.

Abstract: A composition comprising stabilised organo-silanol compounds, said composition comprising two different organo-silanols and an organo-silanol(s) stabilising/complexing agent.

Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

Abstract: The present disclosure is directed to providing a moldable solid washing agent composition and an article molded from the same. The composition of the present disclosure can be stored easily at room temperature for a long time. It is applicable to a system that can be manufactured on site and can satisfy customer needs because it can be molded immediately by a simple method and the shape, size, etc. can be controlled. In addition, the solid washing agent composition disclosed in the present specification has superior compatibility with water.

Abstract: A personal care formulation is provided comprising: multistage polymer, comprising: acrylate rich stage comprising: (a) structural units of monoethylenically unsaturated non-ionic, acrylate rich stage monomer selected from C1-22 alkyl (meth)acrylates and mixtures thereof; and (b) carbosiloxane rich stage, comprising: structural units of carbosiloxane monomer of formula (I), wherein a is 0 to 3; wherein d is 0 or 1; wherein R1 is selected from hydrogen, C1-10 alkyl group and aryl group; wherein R2 is selected from hydrogen and C1-10 alkyl group; wherein R8 is —O—Si(CH3)2—O—Si(CH3)3 group; wherein Y is selected from formula (II), (III) and (IV); wherein R4 and R6 are selected from hydrogen and methyl group; wherein R3 and R5 are a C1-10 alkylene group; wherein R7 is C1-10 alkyl group; wherein b is 0 to 4 and wherein c is 0 or 1.

Abstract: A polymer blend is provided comprising: (A) multistage polymer, comprising: acrylate rich stage comprising: structural units of monoethylenically unsaturated non-ionic, acrylate rich stage monomer selected from C1-22 alkyl (meth)acrylates and mixtures thereof; and carbosiloxane rich stage, comprising: structural units of carbosiloxane monomer of formula (I); and (B) silicone-grafted vinyl copolymer, wherein the silicone-grafted vinyl copolymer, comprises: structural units of a vinyl (B) monomer; and structural units of a carbosiloxane dendrimer of formula (V). Also provided are personal care formulations comprising the polymer blend.

Abstract: The present invention is in the field of rinse-off conditioner compositions; in particular, relates to rinse-off conditioner compositions with improved conditioning benefits. Silicones are a commonly used conditioning agent and thus improved deposition of silicones is always desired. It is therefore an object of the present invention to provide improved silicone deposition and also improved sensory of hair. It has been found that the above objects can be achieved by a conditioner composition comprising a specific combination of silicones.

Abstract: An extract of a plant chosen from Tasmannia lanceolata, Drimys winteri, Spilanthes acmella and Polygonum hydropiper is obtained from ground and dried leaves of said plant by supercritical CO2 extraction at a pressure of between 120 and 350 bar and at a temperature from 35 to 60° C. and contains polygodial. A process for obtaining such an extract is disclosed along with compositions comprising, in a physiologically acceptable medium, an effective amount of the extract to promotes wound healing and decrease inflammation in skin disorders.

Abstract: In one aspect, a composition for topical application is provided. The composition comprises a base. Dispersed within the base is elemental silver as a colloidal suspension, and plant extract from at least 6 plants. The plants are selected from the group consisting of Echinacea purpurea, Stellaria media, Aloe vera, Matricaria recutita, Hypericum perforatum, Calendula officinalis, Equisetum arvense, Symphytum officinale, Panax ginseng, Rumex crispus, Arctium lappa, Trifolium pratense, Chelidonium majus, Thuja occidentalis, Urtica dioica, Mahonia aquifolium, and Galium aparine.

Abstract: The present invention relates to microorganisms for use in the treatment and/or prevention of skin conditions by topical application. In particular, the microorganisms are for use in the treatment and/or prevention of loss of skin barrier function, inflammatory conditions and/or growth of pathogenic microorganism. The invention further relates to pharmaceutical or cosmetic compositions or products comprising the microorganisms Provided is also a cosmetic use of the microorganisms or compositions for application on the skin and a cosmetic method, in particular to improve the appearance of the skin.

Abstract: The present invention relates to an injectable pharmaceutical composition containing keratin for preventing hair loss or stimulating hair growth, wherein the composition is excellent in hair follicle generating and hair growth stimulating effects, and thus can be favorably used as a preventive and therapeutic agent for hair loss or a stimulating agent for hair growth.

Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

Abstract: The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

Abstract: An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.

Abstract: The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein the dosage form and the bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: A solid dosage product having a tailored dissolution profile comprises a carrier block defining a plurality of compartments where each respective compartment is configured to receive one or more active pharmaceutical ingredient and the carrier block being digestible within an animal such that each respective active pharmaceutical ingredient is controllably released; and one or more coating layers applied to the carrier block. A method for manufacturing a solid dosage product having a tailored dissolution comprises manufacturing a digestible carrier block where the carrier block defines a plurality of compartments with each respective compartment configured to receive an active pharmaceutical ingredient; filling a respective compartment with a respective active pharmaceutical ingredient; and coating the carrier block with one or more coating layers.

Abstract: The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.

Abstract: Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion. The compositions are used to treat skin diseases, such as acne vulgaris.

Abstract: A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.

Abstract: The present invention relates to microparticles that can be used as drug-loaded hydrogel particles for embolization and a method for manufacturing same. The microparticles of the present invention have a very excellent anticancer agent adsorption ability, a short anticancer agent adsorption time, and a controllable decomposition time when administered in vivo. Therefore, when the microparticles of the present invention are used in chemoembolization, not only the anticancer effect is excellent, but also side effects can be minimized.

Abstract: The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

Abstract: The invention relates to novel compositions comprising urea and amine functionalised silyl containing polymers which, in combination with tackifying resins, are used as pressure sensitive adhesives and specifically, drug delivery patches. Said compositions can be synthesised with less difficulty compared to urethane analogues and are compatible with a wide array of different drugs.

Abstract: A discharging mechanism of a medical waste sterilization processing apparatus includes a central processing module, a waste processing module, a sterilization module, a monitoring module, a protection module, and a discharge module. The waste processing module and the sterilization module are communicatively connected to the central processing module, the sterilization module is connected to the waste processing module for sterilizing the waste processing module; the monitoring module is provided at the connection of the sterilization module and the waste processing module and is communicatively connected to the central processing module; the protection module is provided in the waste processing module and communicating with the central processing module; the discharge module is connected to the waste processing module and the protection module for discharging processed medical waste. The apparatus has an emergency treatment function to cope with a leakage situation, thereby improving its safety coefficient.

Abstract: The invention describes a method for the production of a biodegradable superabsorbent composite polymer material, characterized by high absorbency under load. The invention also describes novel composite material made of styrene maleic acid copolymer preferably in salt form and a biopolymer, coated with biodegradable coating agents and crosslinked.

Abstract: Disclosed is a decontamination robot. The robot includes a decontamination box including at least two arrays of ultraviolet LEDs, the two arrays arranged to irradiate an object placed inside the decontamination box from at least two independent directions, the decontamination box further including an interior surface with at least 90% reflectivity of ultraviolet light. The robot also includes a drivetrain including four swerve-drive units, each swerve-drive unit capable of rotating a wheel on an axis of the wheel and capable of orienting the wheel in a plane defined by the axes of the four wheels of the four swerve-drive units, whereby the four swerve-drive units coordinate to generate translational motion of the decontamination robot on a working surface.

Abstract: A shopping cart sterilization system is provided comprising a sealable chamber with front and rear doors and a plurality of light arrays inside the chamber. The arrays comprise at least two horizontal fixtures attached along horizontal edges and at least one ultraviolet light bulb in each fixture for directing ultraviolet light at a cart in the chamber. The system also comprises a motor with pulleys and cables to move the arrays proximate and away from the cart. The system moves the light arrays proximate outer surfaces of the cart. Arrays are arranged in a basket arrangement for lowering into an internal area of the cart. Arrays are moved proximate a handle, a child seat, and wheels of the cart.

Abstract: A system for disinfecting an enclosed space includes a housing, ultraviolet (UV) emitters, a sensor to detect occupancy in or entry into an enclosed space, a UV directing mechanism, and a controller. The housing includes an air flow passageway. When the UV directing mechanism is in the closed state, the UV emitters are positioned in the air flow passageway and transmission of UV electromagnetic radiation into the enclosed space is substantially blocked. UV electromagnetic radiation is transmitted into the enclosed space when the UV directing mechanism is in the at least one open state. Disinfection operations can be activated when the UV directing mechanism is in the open state or the closed state. When the UV directing mechanism is in the open state, the disinfection operation is activated when the sensor indicates no occupancy in or no entry into the enclosed space.

Abstract: Aspects of the invention provide a system for disinfecting a humidifier containing a volume of water. An enclosure, such as a humidifier, includes a first chamber, a second chamber, a humidifier component, a third chamber, and a control unit. The first chamber contains a volume of water and a portion of the water flows into the second chamber. A first set of ultraviolet radiation sources within the first chamber can be configured to generate UV-A radiation, while a second set of ultraviolet radiation sources within the second chamber can be configured to generate UV-C radiation. In operation, the humidifier component adjacent to the second chamber creates water vapor using the portion of the volume of water within the second chamber. The water vapor flows into a third chamber that contains the water vapor and releases the water vapor into the ambient.

Abstract: Provided is a compact ultraviolet irradiation device in which a degree of an adverse effect on the human body is suppressed. The ultraviolet irradiation device includes: a lamp house on the surface of which a light extraction surface is formed; an excimer lamp accommodated in the lamp house, a main emission wavelength of which belongs to a first wavelength band of 190-225 nm; an optical filter that is arranged on the light extraction surface and substantially transmits the ultraviolet light in the first wavelength band and substantially reflect the ultraviolet light of a wavelength of 240-300 nm; and a reflecting surface that is a surface located outside the luminous tube of the excimer lamp and inclined with respect to the light extraction surface, the reflecting surface exhibiting reflectivity with respect to the ultraviolet light in the first wavelength band.

Abstract: The invention relates to a disinfection lighting device (10) comprising a first light source (14), wherein the first light source (14) comprises a solid-state light source, wherein the solid-state light source comprises one or more light emitting diodes (14a, 14b), lasers and/or superluminescent diodes; wherein the first light source (14) is configured to generate first light source light having a first spectral power distribution, wherein the first spectral power distribution comprises first light source light (140) in the UV wavelength range and/or visible wavelength range, a second light source (13), wherein the second light source (13) is configured to generate second light source light (130) having a second spectral power distribution different from the first spectral power distribution, wherein the second spectral power distribution comprise in the UV wavelength range, wherein the second light source (13) is arranged at a distance D from the first light source (14), the second light source (13) comprise

Abstract: Aspects of the present disclosure relate to systems and methods for injection and retraction of a fluid. The system includes a switch configured to be activated, wherein activation of the switch activates an electrical control system. The system further includes a linear actuator that interfaces with the electrical control system. The electrical control system causes the linear actuator to depress a plunger, keep the plunger depressed for a predetermined time, and retract the plunger after the predetermined time. The system further includes a fluid reservoir engageable with the plunger, wherein the depression of the plunger causes fluid to be injected from the fluid reservoir into a connector and the retraction of the plunger causes fluid to be retracted into the fluid reservoir and out of the connector.

Abstract: Described herein is a decontamination device for use in vehicle applications. The decontamination device includes a device body and an ultraviolet (UV) light, and the decontamination device is 12-24 inches in length and has a narrow form factor for fitting into crevices and nooks of a vehicle. The UV light includes a first UV light source disposed on a first side of the device body and a second UV light source disposed on a second side of the device body and that is opposite the first side. The first and second UV light sources are coupled to the device body and configured to move together relative to the device body. The first UV light source is operable to emit light in an opposite direction than light emitted from the second UV light source.

Abstract: The present invention has a special filling (WIE) property parameter value developed using microrheology technology, and thus exhibits improved high viscoelasticity flow properties, has low mobility when injected into skin whilst still maintaining the shape thereof, and thus has excellent soft tissue restoration properties, for example for the cheeks, breasts, nose, lips or bottom, and excellent volume expansion and wrinkle alleviation properties.

Abstract: The present invention provides tissue equivalent scaffold structures and methods of production thereof. Such methods include providing a casting chamber comprising an elongate mould portion, axially disposing a lumen template within the elongate mould portion, and at least partly filling the casting chamber with a gel casting material comprising a matrix of fibrils or fibres and an interstitial fluid phase, such that a portion of the lumen template extends above the casting material. The fluid phase of the gel is allow to flow axially out of the elongate mould portion, in a restricted manner, thereby resulting in axial densification of the gel casting material to form a tissue equivalent tubular scaffold. Tissue equivalent scaffold structures according to the present invention are able to support cell populations both within the walls and on the surface of the construct.

Abstract: The present invention generally relates to an orthopedic implant. Specifically, the present invention relates to an implant that incorporates a purposefully designed material that optimizes bony ingrowth combined with a support material configured to provide structural integrity.